Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ifebemtinib - InxMed

Next Previous
Drug Profile

Ifebemtinib - InxMed

Alternative Names: BI 853520; ifebe; IN-10018

Latest Information Update: 10 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; InxMed
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Focal adhesion protein tyrosine kinase inhibitors; PTK2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase I/II Breast cancer; Head and neck cancer; Malignant melanoma; Ovarian cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours
  • No development reported Uveal melanoma

Most Recent Events

  • 01 Jun 2025 Phase-III clinical trials in Non-small cell lung cancer (First-line therapy) (PO)
  • 01 Jun 2025 Pooled efficacy data from phase I/II trial and phase Ib/II trial in Solid tumours released by InxMed (NCT06166836)(NCT05379946)
  • 17 Jan 2025 Phase-I/II clinical trials in Malignant melanoma (Combination therapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease) in China (PO) (NCT06708663)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top